We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-9.44%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$135M
AUM Growth
-$9.38M
Cap. Flow
+$6.82M
Cap. Flow %
5.06%
Top 10 Hldgs %
99.5%
Holding
11
New
–
Increased
3
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$6.79M
2
EGLT
Egalet Corporation
EGLT
+$444K
3
EDIT icon
Editas Medicine
EDIT
+$34

Top Sells

Rank Stock Value
1
PVLA
Palvella Therapeutics
PVLA
+$424K

Sector Composition

Rank Sector Weight
1 Healthcare 64.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
1
DELISTED
Juno Therapeutics, Inc.
JUNO
$47.3M 35.06%
1,229,512
– –
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$36.2M 26.83%
2,600,410
+461,538
+22% +$6.79M
EGLT
3
DELISTED
Egalet Corporation
EGLT
$14.3M 10.63%
2,889,926
+74,998
+3% +$444K
KYNB
4
Kyntra Bio
KYNB
$28.5M
$13.5M 10.01%
32,887
– –
NBRV
5
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$8.59M 6.38%
4,584
– –
EPIX
6
DELISTED
ESSA Pharma
EPIX
$5.01M 3.71%
84,848
– –
PVLA
7
Palvella Therapeutics
PVLA
$1.98B
$3.64M 2.7%
28,285
-2,764
-9% -$424K
EDIT icon
8
Editas Medicine
EDIT
$399M
$2.56M 1.9%
105,008
+1
+0% +$34
TARA icon
9
Protara Therapeutics
TARA
$226M
$2.01M 1.49%
6,250
– –
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
$1.05M 0.78%
606,100
– –
DRNA
11
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$670K 0.5%
223,457
– –

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q2 2016 Portfolio in Review

As of Q2 2016, Omega Fund Management held 11 positions worth $135M, down 6.5% from $144M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Omega Fund Management deployed $6.82M of net new capital in Q2 2016, adding to 3 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 67% a quarter earlier.

On the sell side, the largest reduction was Palvella Therapeutics, an estimated $424K trimmed.

  • Omega Fund Management added most to Paratek Pharmaceuticals, Inc. in Q2 2016, an estimated $6.79M increase.
  • Omega Fund Management's biggest Q2 2016 reduction was Palvella Therapeutics, cutting an estimated $424K.
  • Omega Fund Management's ten largest holdings make up 100% of its $135M portfolio in Q2 2016.
  • Omega Fund Management opened 0 new positions and closed 0 in Q2 2016.
  • Omega Fund Management's portfolio value fell 6.5% quarter-over-quarter to $135M.

Based on Omega Fund Management's 13F filing for Q2 2016, filed 3 Aug 2016.